Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | POLRMT | O00411 | 1/20 | 0.34 |
| ▸ | BTN3A1 | O00481 | 4/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26337287 | 1.00 | CYP3A4 (0.35) | CYP3A4CYP2C9POLRMTBTN3A1RIPK1 | |
| SCHEMBL26332260 | 0.97 | CYP3A4 (0.34) | CYP3A4CYP2C9POLRMTBTN3A1RIPK1 | |
| SCHEMBL26332281 | 0.97 | CYP3A4 (0.34) | CYP3A4CYP2C9POLRMTBTN3A1RIPK1 | |
| SCHEMBL26342139 | 0.96 | CYP3A4 (0.34) | CYP3A4CYP2C9POLRMTBTN3A1 | |
| SCHEMBL23818825 | 0.96 | CYP3A4 (0.34) | CYP3A4CYP2C9POLRMTBTN3A1 | |
| SCHEMBL23818780 | 0.93 | POLRMT (0.33) | CYP3A4CYP2C9POLRMTBTN3A1 | |
| SCHEMBL23818915 | 0.93 | POLRMT (0.33) | CYP3A4CYP2C9POLRMTBTN3A1 | |
| SCHEMBL26332585 | 0.93 | POLRMT (0.33) | CYP3A4CYP2C9POLRMTBTN3A1 | |
| SCHEMBL26334347 | 0.93 | CYP3A4 (0.36) | CYP3A4CYP2C9POLRMTBTN3A1 | |
| SCHEMBL26342248 | 0.93 | BTN3A1 (0.39) | CYP3A4CYP2C9POLRMTBTN3A1RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767337-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20210284670-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284670-A1 | ANTIVIRAL COMPOUNDS | MAVS, HAVCR2, ZC3HAV1 | CYP3A4 435/4885CYP2C9 1982/4885POLRMT 535/4885 |
| US-11767337-B2 | Antiviral compounds | MAVS, HAVCR2, ZC3HAV1 | CYP3A4 435/4885CYP2C9 1982/4885POLRMT 535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.